Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer

Eur J Cancer. 2018 Feb:90:153-155. doi: 10.1016/j.ejca.2017.10.018. Epub 2017 Nov 23.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab / administration & dosage
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Disease-Free Survival
  • Female
  • Humans
  • Paclitaxel / administration & dosage
  • Treatment Outcome

Substances

  • Bevacizumab
  • Paclitaxel